SRPT
Sarepta Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$22.50
−2.13%Aug 27, 2026, 19:00 UTC
Sarepta Therapeutics shares rose 12% on Thursday, rebounding from July lows, as investors looked ahead to upcoming clinical data.
Source:Aug 24, 2026, 16:02 UTC
Kahn Swick & Foti, LLC initiated an investigation into the officers and directors of Sarepta Therapeutics, Inc. regarding potential breaches of fiduciary duties.
Source:Aug 13, 2026, 07:38 UTC
Bank of America Corp DE increased its stake in Sarepta Therapeutics, Inc. by 26.6% during the second quarter of 2026, acquiring an additional 450,336 shares to hold 2,145,926 shares, as disclosed in a recent SEC filing.
Source:Aug 6, 2026, 01:31 UTC
Sarepta Therapeutics reported its financial results for the quarter ended June 2026.
Jul 27, 2026, 13:19 UTC
Sarepta Therapeutics appointed Michael Severino as its new CEO, effective July 28, succeeding Doug Ingram who is retiring.
Source:Jun 30, 2026, 12:30 UTC
The FDA accepted for filing the supplemental New Drug Applications for AMONDYS 45 and VYONDYS 53 submitted by Sarepta Therapeutics.
Source:Jun 4, 2026, 00:00 UTC
Sarepta Therapeutics elected Douglas S. Ingram, Hans Wigzell, Kathryn J. Boor, Michael Chambers, and Deirdre Connelly as directors on June 4, 2026.